autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells

Developed for: Burkitt lymphoma · chronic lymphocytic leukemia/small lymphocytic lymphoma · grade III lymphomatoid granulomatosis · hairy cell leukemia · intraocular lymphoma · large-cell immunoblastic lymphoma · lymphoblastic lymphoma · MALT lymphoma
+8 more
· mantle cell lymphoma · nodal marginal zone B-cell lymphoma · post-transplant lymphoproliferative disease · primary cutaneous B-cell lymphoma · small intestine lymphoma · splenic marginal zone lymphoma · testicular lymphoma · Waldenstrom macroglobulinemia
Investigated by: City of Hope Medical Center · National Cancer Institute (NCI)

today NCT01815749 · Ph 1

20142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT01815749	Oct 2013 → Jan 2018 overdue	Burkitt lymphoma, MALT lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma +12	City of Hope Medical Center	Active not recruiting	No outcome recorded

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01815749 ↗
Known as	CD19-CAR-specific/truncated EGFR lentiviral vector-transduced autologous T cells	“CD19-CAR-specific/truncated EGFR lentiviral vector-transduced autologous T cells” NCT01815749 ↗
Modality	Cell therapy	“adoptive T-cell immunotherapy” PMID 27118452 ↗ Apr 2016
Route	Intravenous	“Patients receive CD19-CAR-specific/truncated EGFR lentiviral vector-transduced autologous T cells IV on day 2 or 3” NCT01815749 ↗
Target	CD19	“lentivirus expressing CD19-specific chimeric antigen receptors (CARs)” PMID 27118452 ↗ Apr 2016